NMC
PMVP icon

Nine Masts Capital’s PMV Pharmaceuticals PMVP Stock Holding History

Nine Masts Capital’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,607
Closed -$20.8K – 296
2025
Q4 		$20.8K Buy
+16,607
New +$22.2K ﹤0.01% 107

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Nine Masts Capital's PMVP Position: Q1 2026 in Review

Nine Masts Capital sold out of PMV Pharmaceuticals (PMVP) in Q1 2026, closing a stake of 16,607 shares — an estimated $20.8K sold.

Nine Masts Capital first reported a position in PMVP in Q4 2025 and held it in 1 quarter. The position peaked at $20.8K in Q4 2025. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

  • Nine Masts Capital reported no remaining PMV Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Nine Masts Capital sold 16,607 PMV Pharmaceuticals shares in Q1 2026, an estimated $20.8K.
  • Nine Masts Capital first reported a position in PMV Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Nine Masts Capital's PMV Pharmaceuticals position peaked at $20.8K in Q4 2025.
  • 69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on Nine Masts Capital's 13F filing for Q1 2026, filed 13 May 2026.